137 related articles for article (PubMed ID: 37703995)
1. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial.
Majhail NS; Miller B; Dean R; Manghani R; Shin H; Sivaraman S; Maziarz RT
Transplant Cell Ther; 2023 Dec; 29(12):749.e1-749.e5. PubMed ID: 37703995
[TBL] [Abstract][Full Text] [Related]
2. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
Khera N; Edwards ML; Song Y; Sun R; Manghani R; Shin H; Simantov R; Signorovitch J; Sivaraman S; Gergis U
Adv Ther; 2024 Apr; 41(4):1637-1651. PubMed ID: 38427220
[TBL] [Abstract][Full Text] [Related]
3. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P; Mazor RD; Yackoubov D; Levy S; Stiff P; Rezvani A; Hanna R; Wagner J; Keating A; Lindemans CA; Karras N; McGuirk J; Hamerschlak N; López-Torija I; Sanz G; Valcarcel D; Horwitz ME
Transplant Cell Ther; 2023 Aug; 29(8):517.e1-517.e12. PubMed ID: 37120136
[TBL] [Abstract][Full Text] [Related]
4. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz ME; Stiff PJ; Cutler C; Brunstein C; Hanna R; Maziarz RT; Rezvani AR; Karris NA; McGuirk J; Valcarcel D; Schiller GJ; Lindemans CA; Hwang WYK; Koh LP; Keating A; Khaled Y; Hamerschlak N; Frankfurt O; Peled T; Segalovich I; Blackwell B; Wease S; Freedman LS; Galamidi-Cohen E; Sanz G
Blood; 2021 Oct; 138(16):1429-1440. PubMed ID: 34157093
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
Lin C; Sajeev G; Stiff PJ; Brunstein CG; Cutler C; Sanz G; Lindemans CA; Rezvani AR; Hanna R; Koh LP; Maziarz RT; Hwang WYK; Song Y; Liu Q; Manghani R; Sivaraman S; Signorovitch J; Horwitz ME; Sung AD
Transplant Cell Ther; 2023 Jan; 29(1):52.e1-52.e9. PubMed ID: 36179986
[TBL] [Abstract][Full Text] [Related]
6. Omidubicel: First Approval.
Heo YA
Mol Diagn Ther; 2023 Sep; 27(5):637-642. PubMed ID: 37354365
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation with omidubicel in sickle cell disease.
Parikh S; Brochstein JA; Galamidi E; Schwarzbach A; Kurtzberg J
Blood Adv; 2021 Feb; 5(3):843-852. PubMed ID: 33560399
[TBL] [Abstract][Full Text] [Related]
8. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.
Ballen KK; Joffe S; Brazauskas R; Wang Z; Aljurf MD; Akpek G; Dandoy C; Frangoul HA; Freytes CO; Khera N; Lazarus HM; LeMaistre CF; Mehta P; Parsons SK; Szwajcer D; Ustun C; Wood WA; Majhail NS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1819-27. PubMed ID: 25064747
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin C; Schwarzbach A; Sanz J; Montesinos P; Stiff P; Parikh S; Brunstein C; Cutler C; Lindemans CA; Hanna R; Koh LP; Jagasia MH; Valcarcel D; Maziarz RT; Keating AK; Hwang WYK; Rezvani AR; Karras NA; Fernandes JF; Rocha V; Badell I; Ram R; Schiller GJ; Volodin L; Walters MC; Hamerschlak N; Cilloni D; Frankfurt O; McGuirk JP; Kurtzberg J; Sanz G; Simantov R; Horwitz ME
Transplant Cell Ther; 2023 May; 29(5):338.e1-338.e6. PubMed ID: 36775201
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G
J Clin Oncol; 2019 Feb; 37(5):367-374. PubMed ID: 30523748
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcomes between unrelated single umbilical cord blood and "ex-vivo" T-cell depleted haploidentical transplantation in children with hematological malignancies.
Gómez-Santos C; González-Vicent M; Molina B; Deltoro N; Herrero B; Ruiz J; Pérez-Martínez A; Diaz MA
World J Pediatr; 2021 Dec; 17(6):609-618. PubMed ID: 34590210
[TBL] [Abstract][Full Text] [Related]
12. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.
Solh M; Brunstein C; Morgan S; Weisdorf D
Biol Blood Marrow Transplant; 2011 May; 17(5):710-6. PubMed ID: 20813199
[TBL] [Abstract][Full Text] [Related]
13. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
Bohannon L; Tang H; Page K; Ren Y; Jung SH; Artica A; Britt A; Islam P; Siamakpour-Reihani S; Giri V; Lew M; Kelly M; Choi T; Gasparetto C; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Horwitz M; Sung A
Transplant Cell Ther; 2021 Aug; 27(8):669.e1-669.e8. PubMed ID: 33991725
[TBL] [Abstract][Full Text] [Related]
14. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
[TBL] [Abstract][Full Text] [Related]
15. Admission of hematopoietic cell transplantation patients to the intensive care unit at the Pontificia Universidad Católica de Chile Hospital.
Escobar K; Rojas P; Ernst D; Bertin P; Nervi B; Jara V; Garcia MJ; Ocqueteau M; Sarmiento M; Ramirez P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):176-9. PubMed ID: 25139214
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
17. The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients.
De Sa H; Maziarz RT; Gandhi AP
Expert Opin Biol Ther; 2024 Mar; 24(3):139-146. PubMed ID: 38481366
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization.
Anand S; Thomas S; Hyslop T; Adcock J; Corbet K; Gasparetto C; Lopez R; Long GD; Morris AK; Rizzieri DA; Sullivan KM; Sung AD; Sarantopoulos S; Chao NJ; Horwitz ME
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1151-1157. PubMed ID: 28392378
[TBL] [Abstract][Full Text] [Related]
19. [Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].
Bautista G; Regidor C; Gonzalo-Daganzo R; Cabrera JR
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():47-51. PubMed ID: 21381288
[TBL] [Abstract][Full Text] [Related]
20. A new beginning: can omidubicel emerge as the next, viable alternative donor source?
Gandhi AP; Newell LF; Maziarz RT
Ther Adv Hematol; 2023; 14():20406207231192146. PubMed ID: 37664800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
